Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients
Oxaliplatin-based reintroduction therapy is a viable strategy in mCRC, particularly for patients with a favorable prior response and prolonged oxaliplatin-free intervals. However, identifying more precise biomarkers is essential to improve patient selection and maximize treatment efficacy.
Authors
- M.A. Rezqallah Aron (ORCID: https://orcid.org/0000-0001-9758-9402)
- Iosune Baraibar (ORCID: https://orcid.org/0000-0002-3500-9641)
- N. Saoudi Gonzalez (ORCID: https://orcid.org/0000-0001-6044-1703)
- J. Tabernero
- A. García (ORCID: https://orcid.org/0000-0001-8388-0522)
- Francesc Salvà (ORCID: https://orcid.org/0000-0001-9240-4907)
- Gualtiero Catani
- R. Dienstmann
- R. Comas (ORCID: https://orcid.org/0000-0003-4115-5095)
- Javier Ros (ORCID: https://orcid.org/0000-0002-8137-5415)
- Fiorella Ruíz‐Pace (ORCID: https://orcid.org/0000-0002-3932-0170)
- Antonio Alcaraz (ORCID: https://orcid.org/0000-0003-2612-5250)
- Elena Élez
- C. Salvà de Torres
- M. Gonzalez Rodriguez (ORCID: https://orcid.org/0000-0001-8289-1158)
Institutions
- Hebron University (PS)
- Vall d'Hebron Institut de Recerca (ES)
- Instituto Alexander Fleming (AR)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100230
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Society for Medical Oncology